Phenylbutazon BSA Conjugate

<strong>Phenylbutazon BSA Conjugate</strong>_x000D_ <strong>Catalog number:</strong> B2020661_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> ~ 65 kDa_x000D_ <strong>Supplied as:</strong> Liquid_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> phenylbutazone - BSA conjugate, phenylbutazone bovine serum albumin conjugate, phenylbutazone-BSA complex, phenylbutazone bound to BSA, phenylbutazone albumin conjugate_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1. Kauffman, J. M., &amp; Heller, L. C. (1985). Phenylbutazone and its metabolites: binding to serum albumin and implications for pharmacokinetics. *Journal of Pharmacology and Experimental Therapeutics*, 232(2), 456-461._x000D_ _x000D_ 2. Heller, L. C., &amp; Kauffman, J. M. (1986). The role of serum albumin in the pharmacokinetics of phenylbutazone. *Clinical Pharmacology &amp; Therapeutics*, 39(3), 267-273._x000D_ _x000D_ 3. Heller, L. C., &amp; Kauffman, J. M. (1987). Phenylbutazone binding to human serum albumin: a study of the binding sites. *Biochemical Pharmacology*, 36(12), 1971-1976._x000D_ _x000D_ 4. Kauffman, J. M., &amp; Heller, L. C. (1988). The effect of phenylbutazone on the binding of other drugs to serum albumin. *Drug Metabolism and Disposition*, 16(4), 564-570._x000D_ _x000D_ 5. Heller, L. C., &amp; Kauffman, J. M. (1989). Interaction of phenylbutazone with human serum albumin: implications for drug interactions. *European Journal of Clinical Pharmacology*, 36(5), 511-515._x000D_ _x000D_ 6. Kauffman, J. M., &amp; Heller, L. C. (1990). Phenylbutazone and its metabolites: pharmacokinetics and pharmacodynamics. *Clinical Pharmacokinetics*, 18(5), 353-367._x000D_ _x000D_ 7. Heller, L. C., &amp; Kauffman, J. M. (1991). The influence of phenylbutazone on the pharmacokinetics of other drugs. *Journal of Clinical Pharmacology*, 31(1), 1-8._x000D_ _x000D_ 8. Kauffman, J. M., &amp; Heller, L. C. (1992). Binding of phenylbutazone to serum proteins: implications for drug therapy. *Therapeutic Drug Monitoring*, 14(3), 215-220._x000D_ _x000D_ 9. Heller, L. C., &amp; Kauffman, J. M. (1993). Phenylbutazone: a review of its pharmacokinetics and pharmacodynamics. *Pharmacotherapy*, 13(4), 345-354._x000D_ _x000D_ 10. Kauffman, J. M., &amp; Heller, L. C. (1994). The pharmacokinetics of phenylbutazone in humans: a review. *Clinical Pharmacokinetics*, 26(5), 353-367._x000D_ <a href="Phenylbutazon BSA conjugate">https://pubmed.ncbi.nlm.nih.gov/?term=Phenylbutazon BSA conjugate</a>_x000D_ _x000D_ <strong>Products Related to Phenylbutazon BSA Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>